New grant from the Bill & Melinda Gates Foundation supports the development of genetic therapies for infectious diseases. Aegis Life and Entos Pharmaceuticals will work collaboratively to utilize the Fusogenix PLV gene therapy delivery platform to develop novel DNA-encoded therapeutics. June 07, 2023 08:00 AM Eastern Daylight
Read more →
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement Supporting Development of Innovative Therapies in Multiple Neurologic Disorders — Combination of Entos’ Fusogenix nucleic acid delivery technology and Lilly’s therapeutic cargo offers potential to overcome a key challenge in delivering nucleic acid therapies to the nervous
Read more →AEGIS LIFE ANNOUNCES START OF PHASE 1/2 TRIAL OF THE ENTOS COVID-19 DNA VACCINE, COVIGENIX VAX-001, WITH FIRST PARTICIPANTS DOSED Published by: Aegis Life Business Wire News Release April 16, 2021 12:26 PM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Aegis Life, Inc. announced today that the first participants
Read more →ENTOS WORKING WITH APPLIED PHARMACEUTICAL INNOVATION TO ENABLE IN-HOUSE DEVELOPMENT AND MANUFACTURING CAPABILITY OF COVID-19 DNA VACCINE Published by: Aegis Life Entos is working with Applied Pharmaceutical Innovation (API) to ensure secure supply of inputs for its vaccine production and the ability to expand its Edmonton facilities.
Read more →ENTOS ANNOUNCES LAUNCH OF US-BASED SPINOUT COMPANY AEGIS LIFE TO SUPPORT ITS GLOBAL VACCINE COMMERCIALIZATION STRATEGY AND SIGNS LICENSE AGREEMENT WITH NTC TO USE NANOSPLASMID VECTOR TECHNOLOGY IN VACCINES Published by: Aegis Life EDMONTON, AB, October 15, 2020 – Entos Pharmaceuticals (Entos), a Canadian biotechnology company developing
Read more →CYTIVA AND ENTOS PHARMACEUTICALS WORK TOGETHER TO ACCELERATE DEVELOPMENT OF COVID19 VACCINES Published by: Aegis Life July 1, 2020 Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method for Entos Pharmaceuticals that will enable GMP-production of the Fusogenix
Read more →ENTOS ANNOUNCES SELECTION OF LEAD DNA VACCINE CANDIDATES FOR COVID-19 AND A $4.2M AWARD TO MOVE FORWARD WITH PHASE I/II HUMAN TRIALS Published by: Aegis Life EDMONTON, AB, June 25, 2020 – Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform,
Read more →ENTOS PHARMACEUTICALS PARTNERS WITH PRECISION NANOSYSTEMS TO ENABLE HIGHLY SCALABLE GMP MANUFACTURING OF FUSOGENIX DNA COVID-19 VACCINE Published by: Aegis Life EDMONTON, Alberta, May 7, 2020 — Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing next generation nucleic acid medicines with their Fusogenix delivery platform announced
Read more →ENTOS PHARMACEUTICALS PARTNERS WITH EPIVAX TO DEVELOP A PAN-CORONAVIRUS DNA VACCINE Published by: Aegis Life EDMONTON, Alberta, April 28, 2020 — Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax,
Read more →